Flualprazolam is a benzodiazepine derivative which was first synthesized in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in Sweden in 2018. It can be described as the 2′-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects to other diazepines (etizolam, flualprazolam, flubromazolam, etc.).
IUPAC Name: 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Molecular Weight: 326.755
InChI Key: MPZVLJCMGPYWQQ-UHFFFAOYSA-N
Moosmann, B; Auwärter, V. Designer benzodiazepines: Another class of new psychoactive substances. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 383-410. 497 kB. https://doi.org/10.1007/164_2018_154 #Flualprazolam